PharmaCyte Biotech (PMCB) Stock News
$PMCB · NASDAQ · HEALTHCARE · 1 stories in 30 daysBORSA has published 1 story on PharmaCyte Biotech (PMCB) in the past 30 days. BORSA’s news read on PMCB is balanced at 50/100, based on 1 company event over the past 7 days. PharmaCyte Biotech’s next earnings report is scheduled for Thursday, Dec 17.
The wire on $PMCB
newest first · updated · direct subject stories onlyThe exchange halted trading in PharmaCyte Biotech (PMCB) shares because of pending news. The reason for the halt and the expected resumption time have not been disclosed.
neutral 50 · impact 30The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.
PharmaCyte Biotech (PMCB) stock: common questions
What is the latest PharmaCyte Biotech stock news?
The highest-impact PMCB story BORSA published in the past 30 days:
· PharmaCyte Biotech (PMCB) Trading Halted for Pending NewsIs the news on PMCB bullish or bearish?
BORSA’s news read on PMCB is balanced at 50/100, based on 1 company event over the past 7 days. It measures the news only: it is separate from price action and is not investment advice.